Virtual visits could make kidney donor counseling easier

NCT ID NCT07206069

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether telemedicine can effectively educate and counsel people considering living kidney donation. Researchers will compare standard in-person care with live video visits. The goal is to see if telemedicine is practical and helps donors make better decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

telemedicine shared decision-making

What this could lead to

If successful, this could show that telemedicine is a practical way to support living kidney donor candidates, potentially improving access to education and counseling.

What could go wrong

This is a small feasibility study with only 70 participants, so results may not apply broadly. It focuses on decision-making, not medical outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Irvine Medical Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••